Line Extension vs. Cannibalization in a Crowded Shelf
A premium skincare brand has one hero product at $48 retail with 55% gross margin and strong repeat purchase. Retail buyers are pressing for a second SKU to fill shelf space, and a competitor has launched a $32 'value' line. The brand team proposes a $34 line extension under the same master brand. Internal estimates: the new SKU would sell 200,000 units in year one, but the team concedes 35% of those buyers would otherwise have bought the $48 hero. The hero's current volume is 500,000 units. The brand's equity rests on a 'clinical premium' positioning reinforced by price. There is no plan yet to differentiate the extension's claims from the hero.
1. Quantify the net contribution effect of the extension and judge whether the cannibalization rate is acceptable.
Read the worked answer
Hero unit margin = $48 × 55% = $26.40.
Extension: assume comparable margin percentage for now; unit margin ≈ $34 × 55% = $18.70. Gross contribution from 200,000 units = $3.74M.
Cannibalized units = 35% × 200,000 = 70,000. Contribution lost on the hero = 70,000 × $26.40 = $1.848M.
Net incremental contribution = $3.74M − $1.848M = $1.892M - positive in isolation.
But the judgment is not purely arithmetic. The 35% rate is high for a line extension; it means over a third of the new SKU's volume is not new demand. The margin per unit is also $7.70 lower, so every cannibalized sale is a double loss (lost hero margin, lower replacement margin). If the true cannibalization is 50%+, net contribution shrinks toward ~$1.1M and the case weakens materially. The estimate should be stress-tested, not accepted at 35%.
2. Beyond the math, what brand-equity risk does the $34 price point create, and how should the extension be designed to mitigate it?
Read the worked answer
The hero's premium is defended by a 'clinical premium' positioning tied to price. A $34 extension under the same master brand, with no differentiated claims, signals that the brand's quality is available cheaper - it resets the reference price downward and invites consumers to trade down within the brand. That erodes the hero's price premium, which is the asset, not just a margin line.
Mitigation:
- Differentiate the extension's claim and use occasion (e.g., a distinct format or need state) so it is not a cheaper version of the hero but a different job.
- Consider sub-branding or a distinct descriptor to create separation from the hero's clinical positioning.
- Guard the hero's price and promotion cadence - do not let the extension's price become the brand's anchor.
- Set a cannibalization ceiling and monitor hero price realization and repeat rates post-launch; if hero premium erodes, pull back.
If the extension cannot be differentiated, the better answer may be to defend the value tier with a separate brand rather than dilute the master brand.